Apellis Pharmaceuticals Inc (APLS) Receives Average Rating of “Buy” from Brokerages

Share on StockTwits

Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $41.40.

APLS has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price target on shares of Apellis Pharmaceuticals in a report on Thursday, December 20th. Citigroup increased their price target on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, December 6th. B. Riley initiated coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 price target on the stock. ValuEngine raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, Zacks Investment Research raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 8th.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Apellis Pharmaceuticals by 1.9% in the 3rd quarter. BlackRock Inc. now owns 2,853,195 shares of the company’s stock valued at $50,730,000 after purchasing an additional 54,227 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Apellis Pharmaceuticals by 5.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after purchasing an additional 72,610 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Apellis Pharmaceuticals by 5.4% in the 3rd quarter. Vanguard Group Inc now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after purchasing an additional 72,610 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 44.5% in the 3rd quarter. Victory Capital Management Inc. now owns 1,347,753 shares of the company’s stock valued at $23,963,000 after purchasing an additional 415,000 shares in the last quarter. Finally, Fiduciary Trust Co. purchased a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at $9,306,000. 55.91% of the stock is owned by institutional investors.

Apellis Pharmaceuticals stock opened at $14.00 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.91 and a current ratio of 14.90. The company has a market cap of $790.45 million, a P/E ratio of -3.81 and a beta of 0.26. Apellis Pharmaceuticals has a 1-year low of $11.45 and a 1-year high of $32.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.05. Research analysts expect that Apellis Pharmaceuticals will post -2.38 EPS for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Further Reading: How Does the Quiet Period Work?

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Dorado Market Capitalization Achieves $58,502.00
Dorado Market Capitalization Achieves $58,502.00
Superior Coin  Market Capitalization Hits $0.00
Superior Coin Market Capitalization Hits $0.00
Rock Achieves Market Capitalization of $6.51 Million
Rock Achieves Market Capitalization of $6.51 Million
Babcock & Wilcox Enterprises  Shares Gap Down to $0.37
Babcock & Wilcox Enterprises Shares Gap Down to $0.37
VF Corp  Expected to Post Quarterly Sales of $3.20 Billion
VF Corp Expected to Post Quarterly Sales of $3.20 Billion
Zacks: United Fire Group, Inc.  Receives Average Recommendation of “Hold” from Analysts
Zacks: United Fire Group, Inc. Receives Average Recommendation of “Hold” from Analysts


© 2006-2019 Ticker Report